CoreCap Advisors’s GSK GSK Stock Holding History

CoreCap Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$137K	Sell	2,852 -123	-4%	-$6.28K	﹤0.01%	990
2026 Q2	$156K	Sell	2,975 -125	-4%	-$6.61K	﹤0.01%	941
2026 Q1	$171K	Sell	3,100 -30	-1%	-$1.63K	0.01%	851
2025 Q4	$153K	Buy	3,130 +121	+4%	+$5.64K	0.01%	877
2025 Q3	$130K	Sell	3,009 -131	-4%	-$5.12K	﹤0.01%	946
2025 Q2	$121K	Buy	3,140 +338	+12%	+$12.9K	﹤0.01%	921
2025 Q1	$109K	Buy	2,802 +717	+34%	+$26.2K	﹤0.01%	875
2024 Q4	$70.5K	Buy	2,085 +104	+5%	+$3.74K	﹤0.01%	1046
2024 Q3	$81K	Sell	1,981 -573	-22%	-$23.4K	﹤0.01%	1004
2024 Q2	$98.3K	Buy	2,554 +481	+23%	+$20.2K	0.01%	505
2024 Q1	$88.9K	Buy	+2,073	New	+$85.5K	﹤0.01%	880
2022 Q4	$70.1K	Buy	+1,996	New	+$66.5K	0.01%	865
2022 Q3	–	Sell	-1,203	Closed	-$66K	–	1154
2022 Q2	$66K	Buy	+1,203	New	+$66.4K	0.01%	847
2022 Q1	–	Sell	-1,992	Closed	-$110K	–	1155
2021 Q4	$110K	Buy	+1,992	New	+$104K	0.01%	720

Other funds holding GSK

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

Bell Bank Fargo, North Dakota $2.66B AUM 18.07% 1-Year Est. Return

Keating Investment Counselors Delray Beach, Florida $382M AUM 16.71% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

CoreCap Advisors's GSK Position: Q3 2026 in Review

CoreCap Advisors reduced its GSK (GSK) stake by 4.1% in Q3 2026, selling an estimated $6.28K and leaving 2,852 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #990.

CoreCap Advisors first reported a position in GSK in Q4 2021 and has held it in 14 quarters since. The position peaked at $171K in Q1 2026. 233 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

CoreCap Advisors held 2,852 shares of GSK worth $137K as of Q3 2026.
CoreCap Advisors sold 123 GSK shares in Q3 2026, an estimated $6.28K.
GSK made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #990 holding.
CoreCap Advisors first reported a position in GSK in Q4 2021 and has held it in 14 quarters since.
CoreCap Advisors's GSK position peaked at $171K in Q1 2026.
233 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.